GlassScriptPhysician profile
Caroline Heys
NPI 1417589318
$6,805.25
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,431 · 2022: $2,425 · 2023: $909 · 2024: $39.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599 · Long Term Medical Supply Or Device Loan: $250 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.81 |
| Long Term Medical Supply Or Device Loan | $249.99 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,054.39 | 2021-2023 | |
| G1 Therapeutics, INC. | $318.17 | 2022-2023 | Cosela |
| Genentech USA, INC. | $275.56 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $265.63 | 2021-2023 | |
| Lilly USA, LLC | $239.82 | 2021-2023 | Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $214.42 | 2021-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $208.90 | 2021-2023 | |
| Janssen Biotech, INC. | $206.97 | 2021-2023 | |
| Genzyme Corporation | $189.48 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $186.95 | 2021-2023 | |
| Astellas Pharma US INC | $186.17 | 2021-2022 | |
| Incyte Corporation | $185.88 | 2021-2023 | Pemazyre, Jakafi |
| Amgen INC. | $155.05 | 2021-2022 | |
| Pfizer INC. | $138.94 | 2021-2023 | |
| Karyopharm Therapeutics INC. | $131.62 | 2021-2023 | Xpovio |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Heys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.